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Protein vaccines, if rendered immunogenic, would facilitate vac-
cine development against HIV and other pathogens. We compared
in nonhuman primates (NHPs) immune responses to HIV Gag p24
within 3G9 antibody to DEC205 (“DEC-HIV Gag p24”), an uptake
receptor on dendritic cells, to nontargeted protein, with or with-
out poly ICLC, a synthetic double stranded RNA, as adjuvant. Prim-
ing s.c. with 60 μg of both HIV Gag p24 vaccines elicited potent
CD4+ T cells secreting IL-2, IFN-γ, and TNF-α, which also prolifer-
ated. The responses increased with each of three immunizations
and recognized multiple Gag peptides. DEC-HIV Gag p24 showed
better cross-priming for CD8+ T cells, whereas the avidity of anti-
Gag antibodies was ∼10-fold higher with nontargeted Gag 24 pro-
tein. For both protein vaccines, poly ICLC was essential for T- and
B-cell immunity. To determine whether adaptive responses could
be further enhanced, animals were boosted with New York vac-
cinia virus (NYVAC)-HIV Gag/Pol/Nef. Gag-speciﬁc CD4+ and CD8+
T-cell responses increased markedly after priming with both pro-
tein vaccines and poly ICLC. These data reveal qualitative differ-
ences in antibody and T-cell responses to DEC-HIV Gag p24 and
Gag p24 protein and show that prime boost with protein and
adjuvant followed by NYVAC elicits potent cellular immunity.
viral vector | Pox virus
Most current vaccines mediate protection primarily throughinduction of antibodies (1). However, in many infections
such as HIV, malaria, and tuberculosis, there remains a need for
protective T-cell immunity. A promising approach under evalua-
tion for such infections is to use prime-boost immunization regi-
mens with heterologous vectors. These include attenuated viral
vectors (2) and protein-based vaccines.The focus of this study is to
assess how different protein vaccine platforms inﬂuence adaptive
immunity in nonhuman primates (NHPs) when used with an im-
mune adjuvant with a viral boost.
For certain infections, protein-based vaccines have been un-
deremphasized due to their limited ability to induce strong Th1
immunity and through cross-presentation, CD8+ T cells. This can
be greatly improved by enhancing uptake by dendritic cells (DCs),
and by using as adjuvants newly recognized, chemically deﬁned
agonists for pattern recognition receptors. These agonists convert
vaccine-capturing DCs from their normal tolerogenic role to a
mature highly immunogenic state (3, 4). One approach to improve
delivery of protein vaccines to DCs is to introduce the protein into
monoclonal antibodies (mAbs) that efﬁciently target DC recep-
tors, and then coadminister the fusion mAb with an appropriate
agonist for DC maturation (5, 6). The outcome of antigen pre-
sentation is also inﬂuenced by the particular DC subset that
presents the antigen (7, 8). In mice, presentation through the
DEC205 DC receptor induces strong Th1 responses and mediates
cross-presentation to CD8+ T cells when administered with an
adjuvant. Among the adjuvants tested, poly ICLC, a synthetic
double-stranded RNA, is a superior innate stimulus for inducing
such T-cell responses in mice (4). To advance this platform, due to
greater similarities in innate immunity, NHPs may provide a more
predictive preclinical model for vaccination of humans.
In this report, we ﬁrst compared the magnitude and quality of
both antibody and T-cell responses in NHPs to the HIV protein,
Gag p24, using nontargeted protein or protein delivered within
a new human mAb against monkey and human DEC205 (9). Our
second major focus was to determine whether T-cell responses in-
ducedby theprotein vaccines could be enhanced after boostingwith
a viral vector. In choosing a viral vector, a number of attenuated
poxviruses have been developed and used in prime-boost regimens
with HIV (10–13). Among these recombinant modiﬁed vaccinia
virus Ankara (MVA) and New York vaccinia virus (NYVAC) are
attenuated forms of vaccinia virus that boost HIV and simian im-
munodeﬁciency virus (SIV) Gag and Env responses in NHPs (14–
20). Here all animals were boosted with a replication defective,
recombinant NYVAC-HIV Gag/Pol/Nef vector (21). We observed
a striking and durable boost in Th1 and CD8+ T-cell responses in
animals primedwith eitherHIVGag p24 protein orDEC-HIVGag
p24 and poly ICLC, compared with responses at the time of the
boost or with NYVAC-HIV Gag/Pol/Nef immunization alone.
Results
HIV Gag p24 and DEC-HIV Gag p24 Plus Poly ICLC Induce Strong and
Durable IFN-γ Producing T-Cell Responses in NHPs. To establish the
activity of our protein vaccines in NHPs, a small pilot study was
initiated in rhesus macaques already immunized with HIV Gag
DNA followed by rAd5-HIV Gag, or rAd5-HIV Gag alone. At
the time of this boosting, there were low levels of HIV Gag-
speciﬁc CD4+ and CD8+ T cells, and we veriﬁed that exposure
to poly ICLC did not boost the low levels of these cytokine se-
creting memory cells in blood. Nontargeted HIV Gag p24 or
DEC-HIV Gag p24 plus poly ICLC each boosted CD4+ T-cell re-
sponses (∼0.5–2.5%) and also, the DEC-targeted vector boosted
CD8+ responses in all NHPs tested (Fig. S1).
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To test the efﬁcacy of protein immunization, we used the s.c.
route to deliver DEC-HIV Gag p24 or nontargeted HIV Gag p24
protein with poly ICLC as adjuvant. Poly ICLC is the synthetic
double-stranded RNA, poly IC, formulated together with poly L-
lysine and carboxymethylcellulose, which induces activation of
TLR 3 andMDA-5 (22). Prior studies in mice have shown that this
approach elicits strong Th1 responses and a low frequency of
CD8+ T cells (3). NHPs were immunized three times with both
forms of HIV Gag p24 with or without poly ICLC, and “empty”
DEC plus poly ICLC as an additional control.
To initially assess the magnitude of the HIV Gag p24-speciﬁc
IFN-γ responses, we used ELISPOT analysis of peripheral blood
mononuclear cells (PBMCs) (Fig. 1A). IFN-γ–producing cells
were detectable [∼200 spot-forming cells (SFC)/106] 2 wk after the
ﬁrst immunization with either HIV Gag p24 protein or DEC-HIV
Gag p24 and poly ICLC. There was a marked increase in the
responses 2 wk after the second immunization (wk 10) followed by
a modest decrease by wk 20. Additional boosting was observed at
wk 29, 2 wk after the ﬁnal or third immunization. Both vaccine
groups had sustained IFN-γ responses at wk 48, ∼5 mo after the
third immunization. At the dose we studied, 60 μg of Gag p24, the
numbers of IFN-γ–producing cells were comparable to HIV Gag
p24 plus poly ICLC or DEC-HIV Gag p24 plus poly ICLC (Fig.
1A), indicating that protein vaccines induce T-cell immunity that
can be boosted and is durable.
To assess cross-priming, we measured IFN-γ by ELISPOT in
CD8+ T cells enriched from PBMCs 2 wk after the second and
third immunizations. DEC targeting was more effective at cross-
priming CD8+ cells (P < 0.05) in all four animals tested (Fig. 1B).
HIV Gag p24 or DEC-HIV Gag p24 Plus Poly ICLC Generates IFN-γ
Responses to Multiple Gag Epitopes. To address the breadth of the
HIVGagp24 responses, PBMCswere stimulatedwith individual 15-
mer peptides spanning the entire HIV Gag p24 protein. Most ani-
malshad IFN-γ responses toat least threeHIVGagepitopes (Fig. 2).
HIV Gag p24 or DEC-HIV Gag p24 Plus Poly ICLC Generates Multi-
functional T Cells. To further characterize the vaccine-induced
CD4+ and CD8+ T cells, PBMCs were stained for markers
denoting central and effector memory cells and simultaneously
analyzed by multiparameter ﬂow cytometry for IFN-γ, IL-2, and
TNF-α by intracellular cytokine staining after a 6-h in vitro stim-
ulation with HIV Gag peptides (Fig. S2A). Cytokines were detec-
ted in both central and effector memory T cells (Fig. S2 B and C).
To detail response kinetics, intracellular cytokine staining was
done after the second (wks 10 and 20) and third (wks 29 and 33)
immunizations. Comparable and robust CD4+ Gag-speciﬁc fre-
quencies were observed in NHPs immunized with HIVGag p24 or
DEC-HIV Gag p24 plus poly ICLC (Fig. 3A, Top). In addition,
animals immunized with DEC-HIV Gag p24 plus poly ICLC in-
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Fig. 1. Immunization with DEC HIV Gag p24 or nontargeted
HIV Gag p24 protein and poly ICLC elicits IFN-γ–producing T
cells. (A) NHPs (four per group) were immunized s.c. three
times at wks 0, 8, and 27 with DEC Gag p24 or HIV Gag p24
and poly ICLC. Additional groups were DEC Gag p24 only (n =
2), HIV Gag p24 protein only (n = 3), or DEC “empty” and
poly ICLC (n = 2). IFN-γ elispots (SFC)/106 PBMCs were quan-
tiﬁed after stimulation by HIV Gag p24 pooled peptides. (B)
As in A but isolated, CD8+ T cells were analyzed after the sec-
ond and third immunizations (means of four NHPs analyzed
in triplicate ± SE from a single experiment. **P < 0.05 from
animals immunized with HIV Gag p24 protein and poly ICLC.
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Fig. 2. Breadth of HIV Gag p24 responses. As in Fig. 1A, but
IFN-γ responses to individual peptides spanning the entire HIV
Gag p24 protein at wk 14 by ELISPOT with each animal as
a separate plot. The number of HIV Gag peptides with >55
SFC/106 cells (dotted line) is noted for each animal.
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duced a small but clearly detectable frequency of Gag-speciﬁc
CD8+ T cells relative to all other vaccine groups (Fig. 3A,Bottom).
To assess the quality of the responding T cells, the relative
proportion of cells making different cytokines were depicted by pie
charts, representing the means for the four animals. Both vaccines
with poly ICLC induced a high frequency of multifunctional IL-2–,
TNF-α–, and IFN-γ–producing CD4+ cells (Fig. 3B). Importantly,
DEC-HIV Gag p24 with poly ICLC also induced a high pro-
portion of multifunctional CD8+ T-cell responses (Fig. 3B, Right,
red section of pie chart). To extend this analysis, PBMCs at wk 33
after vaccination were stimulated with HIV Gag peptides and
supernatants assessed for cytokines and chemokines. Both vac-
cines induced IL-2, IFN-γ, and MIP 1-β but no detectable IL-4,
IL-10, or IL-17 (Fig. S3). TheGag-speciﬁc CD4+ and CD8+ T-cell
responses were also detected in bronchoalveolar lavage. Hence
both vaccines induced strong and durable, multifunctional Th1
responses with DEC-HIV Gag p24 and poly ICLC being more
effective to generate CD8+ T cells in blood.
T Cells Induced by HIV Gag p24 or DEC-HIV Gag p24 Plus Poly ICLC
Proliferate Following Restimulation. A hallmark of T-cell function
is to proliferate following stimulation. Using carboxyﬂuorescein
succinimidyl ester (CFSE) labeling of PBMCs, animals immu-
nized with DEC-HIV Gag p24 and poly ICLC (Fig. S4A), and to
a lesser extent HIV Gag p24 protein and poly ICLC (Fig. S4B),
had increased frequencies of CFSE low cells and production of
IFN-γ (Fig. 3C) from CD4+ T cells following the 5-d culture with
HIV Gag. Consistent with the previous data on cross-priming,
only the DEC-HIV Gag p24 and poly ICLC immunized animals
had consistent proliferation and IFN-γ production from divided
CD8+ T cells (Fig. S4A and Fig. 3C).
HIV Gag p24 Plus Poly ICLC Generates High Titer and Avidity IgG
Antibodies. To assess antibody responses, we carried out ELISAs
on the sera (Fig. 4A). NHPs immunized with both forms of the
protein vaccine had robust total Gag-speciﬁc IgG titers that were
comparable and increased after each immunization. To determine
avidity, surface plasmon resonance (SPR) binding analyses was
used to measure the kinetics of association and dissociation of
serum antibodies with HIV Gag p24 rather than binding at equi-
librium in the ELISAs. Remarkably, whereas high avidity re-
sponses were observed in all animals immunized with HIV Gag
p24 plus poly ICLC, only moderate to low avidity responses were
induced by DEC-HIV Gag p24 plus poly ICLC (Fig. 4B).
Boosting with Recombinant NYVAC Strongly Enhances IFN-γ–
Producing T Cells Following Priming with DEC-HIV Gag p24 or HIV
Gag p24 Plus Poly ICLC. Heterologous prime-boost immunization
with a variety of vaccine vector platforms can substantially increase
immunity compared with homologous prime boosting. Here, 31
wk after the third immunization with the HIV Gag p24 protein
vaccines, NHPs were boosted with NYVAC-HIV Gag/Pol/Nef
(21). To control for the inﬂuence of the NYVAC-HIV Gag/Pol/
Nef immunization alone, a group of six naïve animals was added to
the study. There were still sizeable (∼1%)CD4+ IFN-γ–producing
T cells 31 wk after the last immunization with DEC-HIV Gag p24
or HIV Gag p24 protein + poly ICLC, which was the time of the
NYVAC-HIV Gag/Pol/Nef boost (Fig. 5A, Top Left). After a sin-
gle boost, all primed animals had an approximately two- to four-
fold increase in the frequency of CD4+ IFN-γ–producing cells at
the peak, which remained stable up to 16 wk (Fig. S5 A and B). By
contrast, there were low to undetectable CD4+ IFN-γ responses in
animals boosted with NYVAC after priming with only HIV Gag
p24 or DEC-HIV Gag p24 protein alone, and empty DEC and
poly ICLC (Fig. 5A). There also was a striking increase in the
frequency of CD8+ IFN-γ–producing cells in animals primed with
DEC-HIV Gag p24 or HIV Gag p24 protein and poly ICLC fol-
lowed by theNYVAC-HIVGag/Pol/Nef boost, compared with the
other primed animals or those immunized with NYVAC-HIV
Gag/Pol/Nef alone (Fig. 5B, Right). When a second boost with
NYVAC-HIV Gag/Pol/Nef boost was given 16 wk later, it did not
further enhance the robust memory T-cell responses in both
protein vaccine groups (Fig. 5C). These data show that a single
immunization of replication defective recombinant NYVAC-HIV
Gag/Pol/Nef elicits low to undetectable HIV Gag-speciﬁc T-cell
immunity but as a boost, it leads to a major increase in the mag-
nitude of CD4+ and CD8+ IFN-γ–producing T cells in animals
primed with protein vaccine and poly ICLC.
NYVAC Boosting Generates Multifunctional CD4+ and CD8+ Cytokine-
Producing T Cells with a Similar Breadth to Those Elicited by Protein
Priming. The quality of the prime-boosted responses showed that
both CD4+ and CD8+ T cells (Fig. S6 A and B) were highly poly
functional and remained stable over 10 wk after the two protein
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Fig. 3. Features of HIV Gag-speciﬁc CD4+ and CD8+ T-cell cy-
tokine responses. (A) Frequency of Gag-speciﬁc cytokine (IFN-γ,
IL-2, or TNF-α) producing CD4+ and CD8+ T cells in PBMCs by
multiparameter ﬂow cytometry at indicated times. (B) As in A,
but polyfunctionality of the cytokine responses in frozen
PBMCs in a batch analysis, was assessed by SPICE analysis and
depicted as pie charts to show relative proportions of seven
populations producing different combinations of IFN-γ, IL-2, or
TNF-α. Mean of each population’s percentages from four NHPs
per group at wks 10 and 29. # denotes a difference from ani-
mals immunized with HIV Gag p24 protein and poly ICLC (P <
0.05) at wk 29. (C) CFSE-labeled PBMCs were cultured 5 d ± the
entire pool of HIV Gag p24 peptides. The entire pool of HIV
Gag peptides was added for 12 h and the frequency of IFN-γ–
producing cells assessed by ﬂow cytometry. Dots are individual
animals and bars the interquartile range.
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vaccines. Furthermore, the breadth of T-cell responses was com-
parable before and after boosting (Fig. 6). Thus, a robust, broad,
durable, and polyfunctional CD4+ and CD8+ T-cell response is
generated by boosting a relatively low frequency of cross-primed
CD8+ T cells induced by a protein vaccine with a single immuni-
zation with NYVAC-HIV Gag/Pol/Nef.
Discussion
Here we show that our selected adjuvant, poly ICLC, was essential
to generate antibody and T-cell immunity to nontargeted and
DEC-targeted protein vaccines, highlighting the efﬁcacy of poly
ICLC as an adjuvant in NHPs with only two immunizations. We
uncovered differences in the way DC-targeted and -nontargeted
protein vaccines inﬂuence the magnitude and quality of the T-cell
and antibody response with the same adjuvant in NHPs.With poly
ICLC as an adjuvant, and a 60-μg dose of protein, both non-
targeted and DEC-targeted HIV Gag p24 protein induced po-
tent multifunctional Th1 responses that also had considerable
breadth and durability. Such multifunctional responses prospec-
tively correlated with protection against Mycobacterium tubercu-
losis, Leishmania major, and vaccinia virus models of infection in
mice (23–25).
In contrast to CD4+ T-cell responses, DEC targeting of HIV
Gag p24 allowed for the better induction and recall of CD8+ T-cell
immunity. The cross-priming byDEC-targetedHIVGag appeared
more effective as assessed by assays for cytokine-producing CD8+
T cells, proliferative capacity, and for long-livedmemory responses
that could be boosted by recombinant NYVAC-HIVGag/Pol/Nef.
Conceivably the value of DEC targeting results from improved
intracellular trafﬁc and/or processing of HIV Gag in DCs via the
DEC receptor or superior cross-presenting features in the DC
subsets that express DEC. CD8+ T-cell responses to protein vac-
cines have been observed in other NHP studies but required
conjugation of the protein to a TLR7/8 agonist (26) or the protein
needed to be emulsiﬁed in montanide with the TLR 7/8 agonist
(27); but in these studies, DC targeting was not assessed. CD8+
T-cell immunity has also been generated in NHPs using a hepatitis
C virus (HCV) core protein adsorbed onto immune-stimulating
complexes (ISCOMs) (28) or a trimeric HIV Env protein given
with ISCOMS and CpG (29). These data suggest that various
aspects of formulation, which include the nature of the protein itself
and DC targeting, will signiﬁcantly inﬂuence cross-presentation.
In terms of adjuvants, a common feature between TLR 7/8
agonists and poly ICLC is the efﬁcacy in inducing type I IFN, which
enhances cross-presentation (30) and is essential for poly IC to
render DC immunogenic (4). The formulation of poly ICLC
whereby poly IC is complexed with poly L-lysine and carboxy-
methylcellulose was designed to prolong its effects in vivo (31).
Recent studies inmice withDEC-targetedHIVGag (3) or inNHPs
with nontargeted keyhole limpet hemocyanin (KLH) (32), showed
that poly ICLC was effective in generating CD4+ T-cell responses.
In a separate NHP study using the malaria circumsporozoite (CSP)
protein and poly IC rather than poly ICLC, we did not observe
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CD8+ T-cell responses (33). To assess the safety of poly ICLC, in
a separate ongoingNHP vaccine study with anHIVEnv protein, we
observed no signiﬁcant adverse events on the basis of blood counts,
serum chemistries, and a series of clinical parameters. Moreover,
poly ICLC has been administered to humans withoutmajor toxicity.
Synthetic double-stranded RNAs lead to enhanced B-cell ac-
tivation and antibody production in mice (34) and also NHPs
(32, 33, 35, 36). We conﬁrmed these ﬁndings, but surprisingly, we
found that the avidity of Gag-speciﬁc antibodies was lower with
the DEC-targeted vaccine. This likely results from DEC205 ex-
pression by all germinal center B cells, so that processing of Gag
by Gag-nonspeciﬁc B cells distracts the helper T cells required
for high-afﬁnity antibody formation (37).
Our second set of ﬁndings was to further optimize HIV Gag-
speciﬁc T-cell immunity using heterologous prime-boost immuni-
zation. Prior studies in NHPs using SIV Gag antigen showed that
immunization with DNA followed byMVA (15, 16, 38) or NYVAC
(17, 39) strongly enhanced SIV Gag-speciﬁc CD8+ responses
compared with DNA or poxvirus immunization alone, as detected
with Gag-speciﬁc tetramer or ELISPOTs. Such responses were
functional, as determined by cytotoxic T-lymphocyte (CTL)
assays or production of IFN-γ by intracellular cytokine staining
(ICS) and correlated with some control of infection following
challenge. However, in one study where NHPs were primed with
DNA and boosted with either fowlpox, MVA, or vaccinia virus
encoding SIV Gag, all of the poxviruses vaccines were compara-
ble in their ability to boost SIV Gag-speciﬁc CD8+ T-cell im-
munity, compared with homologous DNA prime and boost, but
there was a rapid decay of the responses at memory time points
(20). We suggest that the durability of the CD8+ T-cell responses
with our prior prime-boost regimens resulted from the large
CD4+ T-cell responses during priming, which could have helped
CD8+ responses.
With respect to prior work usingHIVGag antigens to immunize
NHPs, DNA vaccines containing full-length HIVGag or a speciﬁc
peptide have been used to prime animals followed by recombinant
fowlpox virus (rFPV) (14) or MVA (40) boost. Priming led to
increased proliferative responses and CD8+ T-cell immunity as
determined by CTL assays (14) or by direct staining with a tetra-
mer or ICS following a prolonged (7–10 d) in vitro culture with
antigen (40). Here we show that cross-primed HIV Gag-speciﬁc,
cytokine-producing, effector CD8+ T cells, induced by DEC HIV
Gag and to a lesser extent HIVGag p24 protein together with poly
ICLC, are strongly enhanced following a single boost with
NYVAC-HIV Gag/Pol/Nef. The magnitude of these responses
compare favorably with those observed following prime-boost
immunization using DNA prime and Ad-5 or MVA HIV Gag
boost (41) or Ad5-HIV Gag prime followed by MVA-HIV Gag
boost (19). Although it is difﬁcult to directly compare immunity
achieved in different NHP studies with various vectors and inserts,
the magnitude, quality, and durability of the CD4+ Th1 and CD8+
T-cell responses after the NYVAC boost in this study are notable.
The observed dichotomy in the potency of NYVAC-HIV Gag/
Pol/Nef as a boost compared with its limiting priming for T-cell
responses is consistent with prior studies in NHPs and humans
using a variety of pox virus vectors and antigens (11, 13). Due to
the large number of viral peptides potentially presented from
a poxvirus, competition for antigen may limit induction of T cells
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CD8+ T-cell IFN-γ responses before and
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speciﬁc for the insert. By contrast, the amount of antigen needed
to boost memory CD8+ T cells may be less stringent. Innate
response induced by NYVAC could also play a critical role in
expanding memory T-cell responses.
The studies reported here need to be extended to human
subjects to verify whether our heterologous prime-boost immu-
nization with vectors and protein vaccines is a logical vaccine
approach to optimize both humoral and cellular immunity and
protection against AIDS, malaria, and tuberculosis.
Materials and Methods
Immunizations. To prime NHPs, animals were immunized three times s.c. in the
groin with 60 μg HIV Gag p24 protein, with or without 1 mg of poly ICLC, or
200 μg DEC-Gag p24 (containing 60 μg HIV Gag p24) with or without 1 mg of
poly ICLC. All injections were given in a total volume of 1 mL in a single site
s.c. at wks 0, 8, and 27. For boosting, all primed animals received an injection
of NYVAC-HIV Gag/Pol/Nef (108 pfu in 0.5 mL) intramuscular (i.m.) 31 wk
after the last protein immunization (wk 58).
Additional materials and methods are provided in SI Materials and
Methods.
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